<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586858</url>
  </required_header>
  <id_info>
    <org_study_id>ML27815</org_study_id>
    <nct_id>NCT01586858</nct_id>
  </id_info>
  <brief_title>Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study</brief_title>
  <acronym>RAVELOS</acronym>
  <official_title>Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab is the first drug approved by the United States Food and Drug Administration (FDA)
      for the treatment of patients with granulomatosis with polyangiitis (Wegener's
      granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the
      long-term safety and efficacy of this drug is not yet clear. This study proposes to follow
      patients who were enrolled in the RAVE study to determine if treatment with rituximab
      influences long-term outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2012</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety of rituximab for the treatment of ANCA-associated vasculitis</measure>
    <time_frame>Four years</time_frame>
    <description>To determine the long-term safety of rituximab for the treatment of ANCA-associated vasculitis (granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>Four years</time_frame>
    <description>Disease activity, assessed by the proportion of patients with severe flares</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease damage</measure>
    <time_frame>Four years</time_frame>
    <description>Disease damage, assessed by the increase in VDI and AVID scores from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal survival</measure>
    <time_frame>Four years</time_frame>
    <description>Renal survival, assessed by the proportion of patients doubling their serum creatinine, reaching Stage V Chronic Kidney Disease (defined as a glomerular filtration rate â‰¤15 ml/min), or both.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy</measure>
    <time_frame>Four years</time_frame>
    <description>Proporition of patients with incident malignancies, including type of malignancy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <arm_group>
    <arm_group_label>RAVE subjects</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational study of subjects previously enrolled in the RAVE trial</description>
    <arm_group_label>RAVE subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RAVE study participants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Enrollment in the RAVE trial

          2. Completion of RAVE Common Closeout Date visit

          3. Informed consent

        Exclusion Criteria:

          1. Refusal to participate

          2. Inability to comply with standard-of-care, including routine clinical visits and
             testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.</citation>
    <PMID>20647199</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 25, 2012</lastchanged_date>
  <firstreceived_date>April 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Philip Seo</investigator_full_name>
    <investigator_title>Director, the Johns Hopkins Vasculitis Center</investigator_title>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>ANCA</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Small vessel vasculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
